108 research outputs found

    Positive parenting style and positive health beyond the authoritative: Self, universalism values, and protection against emotional vulnerability from Spanish adolescents and adult children

    Get PDF
    IntroductionRecent research is fully questioning whether the combination of parenting warmth and strictness (the authoritative style) is always identified as positive parenting across the globe. This study analyzes parenting styles and the positive health of adolescents and adult children.MethodsThe sample was 2,090 Spanish children (59.9% women), from four age groups: 600 adolescents, 591 young adults, 507 middle-aged adults, and 392 older adults. Parenting styles (indulgent, authoritative, authoritarian, and neglectful) were obtained by warmth and strictness measures. Children’s positive health was measured by self (family self-concept, self-esteem, and negative self-efficacy), universalism values, and emotional vulnerability.ResultsThe main results showed that the indulgent parenting style was associated with equal and even better scores than the authoritative style, whereas the authoritarian and neglectful styles were consistently associated with low scores in positive health indicators for all age groups. However, two triple interactions of sex by age group by parenting style showed that women children from neglectful families reported the lowest family self-concept in old age and the highest emotional vulnerability in middle age.DiscussionThe study findings question the universal benefits of the so-called positive parenting (the authoritative style) for positive health

    Analyzing when parental warmth but without parental strictness leads to more adolescent empathy and self-concept: Evidence from Spanish homes

    Get PDF
    IntroductionClassical research mainly conducted with European-American families has identified the combination of warmth and strictness (authoritative style) as the parenting always associated with the highest scores on developmental outcomes. Additionally, despite the benefits of empathy for prosocial behaviors and protection against antisocial behaviors, most research has considered the contribution of specific practices (e.g., reasoning or power assertion), but not so much the parenting styles. Similarly, family studies tend to study the relationship between parenting and global self-perceptions (self-esteem), but not so much those of each dimension (self-concept).MethodsIn the present study, 600 Spanish adolescents from 12 to 17 years old (M = 15.25, SD = 2.01) were classified within one of the four household typologies (i.e., authoritative, indulgent, authoritarian, or neglectful). Adolescent developmental outcomes were cognitive empathy (adopting perspectives and emotional understanding), emotional empathy (empathic stress and empathic happiness), and self-concept (academic, social, emotional, family and physical).ResultsThe results showed that the indulgent parenting (warmth but not strictness) was related to equal or even better empathy and self-concept than the authoritative style (warmth and strictness), whereas non-warm parenting (authoritarian and neglectful) was consistently associated with poor results.DiscussionOverall, the present findings seriously question that parental strictness combined with parental warmth (authoritative style) is always the parenting style related to the greatest outcomes. By contrast, it seems that reasoning, warmth and involvement, without strictness (indulgent parenting) help adolescents to achieve a good orientation toward others in terms of cognitive and affective empathy and a good self-evaluation in terms of self-concept

    A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Several human pathologies, including neoplasia and ischemic cardiovascular diseases, course with an unbalance between oxygen supply and demand (hypoxia). Cells within hypoxic regions respond with the induction of a specific genetic program, under the control of the Hypoxia Inducible Factor (HIF), that mediates their adaptation to the lack of oxygen. The activity of HIF is mainly regulated by the EGL-nine homolog (EGLN) enzymes that hydroxylate the alpha subunit of this transcription factor in an oxygen-dependent reaction. Hydroxylated HIF is then recognized and ubiquitinilated by the product of the tumor suppressor gene, pVHL, leading to its proteosomal degradation. Under hypoxia, the hydroxylation of HIF by the EGLNs is compromised due to the lack of oxygen, which is a reaction cosubstrate. Thus, HIF escapes degradation and drives the transcription of its target genes. Since the progression of the aforementioned pathologies might be influenced by activation of HIF-target genes, development of small molecules with the ability to interfere with the HIF-regulatory machinery is of great interest.</p> <p>Results</p> <p>Herein we describe a yeast three-hybrid system that reconstitutes mammalian HIF regulation by the EGLNs and VHL. In this system, yeast growth, under specific nutrient restrictions, is driven by the interaction between the β domain of VHL and a hydroxyproline-containing HIFα peptide. In turn, this interaction is strictly dependent on EGLN activity that hydroxylates the HIFα peptide. Importantly, this system accurately preserves the specificity of the hydroxylation reaction toward specific substrates. We propose that this system, in combination with a matched control, can be used as a simple and inexpensive assay to identify molecules that specifically modulate EGLN activity. As a proof of principle we show that two known EGLN inhibitors, dimethyloxaloylglycine (DMOG) and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamide (S956711), have a profound and specific effect on the yeast HIF/EGLN/VHL system.</p> <p>Conclusion</p> <p>The system described in this work accurately reconstitutes HIF regulation while preserving EGLN substrate specificity. Thus, it is a valuable tool to study HIF regulation, and particularly EGLN biochemistry, in a cellular context. In addition, we demonstrate that this system can be used to identify specific inhibitors of the EGLN enzymes.</p

    Tomografía por emisión de positrones (PET) en oncología clínica no neurológica

    Get PDF
    Objetivos: Se recogen los resultados de una revisión de la literatura científica sobre la eficacia diagnóstica de la PET en algunas condiciones oncológicas, exceptuando los tumores cerebrales. Se han analizado los parámetros diagnósticos de sensibilidad (Se), especificidad (Sp) y exactitud diagnóstica, en comparación (cuando ha sido posible) con otras tecnologías de imagen alternativas.Introducción, Objetivo y Ámbito del Informe, Métodos y resultados generales de la revisión sistemática de la evidencia científica, Resultados clínicos de la revisión sistemática de la evidencia científica, Resultados de la revisión no sistemática en otros cánceres, Discusión, Conclusiones. Anexo I: Cobertura en EE.UU. y Canadá, Anexo II: Fichas bibliográficas del estudio 1996, analizadas por la AETS. Referencias

    Eficacia de la vacuna meningocócica de polisacárido capsular del grupo C

    Get PDF
    Este informe consiste esencialmente en una revisión sistemática de la literatura científica sobre los efectos, intensidad y duración de la respuesta serológica, así como sobre la eficacia, efectividad y seguridad de la vacuna meningocócica de polisacárido capsular del grupo C.Resumen, Abstract, Abstract INAHTA, Presentación, Introducción Etiología, distribución, diagnóstico, Situación actual de la enfermedad meningocócica en España, Portadores, mecanismo de transmisión e inmunidad, Vacuna meningocócica de polisacáridos capsulares purificados de los grupos A y C, Eficacia y seguridad de la vacuna meningocócica de polisacáridos capsulares purificados de los grupos A y C, Método Eficacia, Inicio de efecto protector, Duración, Reacciones adversas Interacciones, Revacunación, Indicaciones de la vacuna, Recomendaciones sobre el uso de la vacuna meningocócica de polisacárido capsular del grupo C de instituciones y asociaciones profesionales, Resumen Bibliografía

    A model of neutrino mass and dark matter with large neutrinoless double beta decay

    Get PDF
    We propose a model where neutrino masses are generated at three loop order but neutrinoless double beta decay occurs at one loop. Thus we can have large neutrinoless double beta decay observable in the future experiments even when the neutrino masses are very small. The model receives strong constraints from the neutrino data and lepton flavor violating decays, which substantially reduces the number of free parameters. Our model also opens up the possibility of having several new scalars below the TeV regime, which can be explored at the collider experiments. Additionally, our model also has an unbroken Z2 symmetry which allows us to identify a viable Dark Matter candidate

    Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

    Get PDF
    Background: Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods: We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings: Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation: This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding: Sanofi and Regeneron Pharmaceuticals

    Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

    Get PDF
    Background: Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. This scoping review is aimed at the description and analysis of the strategies used in high-income countries to reengage LTFU in HIV care, their implementation and impact. Methods: A scoping review was done following Arksey & O'Malley's methodological framework and recommendations from Joanna Briggs Institute. Peer reviewed articles were searched for in Pubmed, Scopus and Web of Science; and grey literature was searched for in Google and other sources of information. Documents were charted according to the information presented on LTFU, the reengagement procedures used in HIV units in high-income countries, published during the last 15 years. In addition, bibliographies of chosen articles were reviewed for additional articles. Results: Twenty-eight documents were finally included, over 80% of them published in the United States later than 2015. Database searches, phone calls and/or mail contacts were the most common strategies used to locate and track LTFU, while motivational interviews and strengths-based techniques were used most often during reengagement visits. Outcomes like tracing activities efficacy, rates of reengagement and viral load reduction were reported as outcome measures. Conclusions: This review shows a recent and growing trend in developing and implementing patient reengagement strategies in HIV care. However, most of these strategies have been implemented in the United States and little information is available for other high-income countries. The procedures used to trace and contact LTFU are similar across reviewed studies, but their impact and sustainability are widely different depending on the country studied

    The Compact Linear Collider (CLIC) - 2018 Summary Report

    Get PDF
    corecore